Abstract
Tuberculosis (TB) kills more youth and adults than any other infectious disease in the world today. The emergence of new strains of Mycobacterium tuberculosis resistant to some or all current antituberculosis drugs is a serious and crescent problem. The resistance is often a corollary to HIV infection and drug-resistant TB is more difficult and more expensive to treat, besides to be more likely fatal. Thus, it is still necessary to search for new antimycobacterial agents. The identification of novel targets need the identification of biochemical pathways specific to mycobacteria and related organisms. Many unique metabolic processes occur during the biosynthesis of mycobacterial cell wall components. In this report, we examine one of these attractive targets for the rational design of new antituberculosis agents - the mycolic acids.
Current Drug Targets
Title: An Approach for the Rational Design of New Antituberculosis Agents
Volume: 2 Issue: 4
Author(s): K. F. M. Pasqualoto and E. I. Ferreira
Affiliation:
Abstract: Tuberculosis (TB) kills more youth and adults than any other infectious disease in the world today. The emergence of new strains of Mycobacterium tuberculosis resistant to some or all current antituberculosis drugs is a serious and crescent problem. The resistance is often a corollary to HIV infection and drug-resistant TB is more difficult and more expensive to treat, besides to be more likely fatal. Thus, it is still necessary to search for new antimycobacterial agents. The identification of novel targets need the identification of biochemical pathways specific to mycobacteria and related organisms. Many unique metabolic processes occur during the biosynthesis of mycobacterial cell wall components. In this report, we examine one of these attractive targets for the rational design of new antituberculosis agents - the mycolic acids.
Export Options
About this article
Cite this article as:
M. Pasqualoto F. K. and Ferreira I. E., An Approach for the Rational Design of New Antituberculosis Agents, Current Drug Targets 2001; 2 (4) . https://dx.doi.org/10.2174/1389450013348227
DOI https://dx.doi.org/10.2174/1389450013348227 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rational Design and Evaluation of the Recombinant Multiepitope Protein
for Serodiagnosis of Rubella
Current Pharmaceutical Biotechnology Effect of Vitamin D Supplementation in Type 2 Diabetes Patients with Tuberculosis: A Systematic Review
Current Diabetes Reviews Preface
Current Drug Targets - Infectious Disorders Inflammation in Fish As Seen from A Morphological Point of View with Special Reference to the Vascular Compartment
Current Pharmaceutical Design Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Targeting Bacterial RNA Polymerase: Promises for Future Antisense Antibiotics Development
Infectious Disorders - Drug Targets Synthesis of Coumarin-benzotriazole Hybrids and Evaluation of their Anti-tubercular Activity
Letters in Organic Chemistry Dendritic Cells and Macrophages: Same Receptors but Different Functions
Current Immunology Reviews (Discontinued) Polymorphic Receptors of the Innate Immune System (MBL/MASP-2 and TLR2/4) and Susceptibility to Pneumococcal Bacteremia in HIV-Infected Patients: A Case-Control Study
Current HIV Research Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Insights into sRNA Genes Regulated by Two-Component Systems in the <i>Bacillus cereus</i> Group
Current Bioinformatics Fcγ Receptor 1 (CD64), a Target Beyond Cancer
Current Pharmaceutical Design Plombage: A Forgotten Surgical Treatment for Pulmonary Tuberculosis
Current Respiratory Medicine Reviews A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
Current Drug Metabolism Statistical Molecular Design of Balanced Compound Libraries for QSAR Modeling
Current Medicinal Chemistry 3-(1-Adamantylthio)-4-Phenylpyridine as a Potential Therapeutic for Methicillin-Resistant Staphylococcus aureus
Letters in Drug Design & Discovery Ester of Quinoxaline-7-carboxylate 1,4-di-N-oxide as Apoptosis Inductors in K-562 Cell Line: An in vitro, QSAR and DFT Study
Anti-Cancer Agents in Medicinal Chemistry Vitamin D Metabolism Genes in Asthma and Atopy
Mini-Reviews in Medicinal Chemistry Drug Targets from Human Pathogenic Amoebas: Entamoeba histolytica,Acanthamoeba polyphaga and Naegleria fowleri
Infectious Disorders - Drug Targets HIV Nef: Role in Pathogenesis and Viral Fitness
Current HIV Research